Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-09-15

Clinical Trial Update: NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922) [Phase 1]

View source ↗

Summary

This update reports the completion of a Phase 1 study of lorlatinib (PF-06463922) in neuroblastoma. Results from the trial have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • lorlatinib (lorlatinib)

Snippet

Sponsor: New Approaches to Neuroblastoma Therapy Consortium | Conditions: Neuroblastoma | Phase 1 | Status: COMPLETED | Results posted: 2025-09-15